The purpose of this study is to evaluate the oral bioavailability of two new tablet
formulations of TAK-385 (T4 Formulation B and T4 Formulation C) under fasted and fed
conditions, relative the T2 Formulation tablet; and to estimate the effect of food on the
pharmacokinetics (PK) of a single oral dose of the T4 Formulation B tablet and the T4
Formulation C tablet.